查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1722823

癌症/腫瘤分析市場報告：規模、佔有率、趨勢及預測（按癌症類型、技術、技巧、應用和地區），2025 年至 2033 年

Cancer/Tumor Profiling Market Report Size, Share, Trends, and Forecast by Cancer Type, Technology, Technique, Application, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

2024 年全球癌症/腫瘤分析市場規模價值 124.7 億美元。展望未來， IMARC Group估計到 2033 年市場規模將達到 262.9 億美元，2025-2033 年期間的複合年成長率為 8.21%。北美目前佔據市場主導地位，到 2024 年將佔據超過 42.8% 的市場。精準醫療的進步、癌症盛行率的上升以及個人化治療方法的日益普及推動了市場顯著成長。對基於生物標記的診斷的需求不斷成長，加上基因組和蛋白質組分析的技術創新，進一步推動了市場擴張。

癌症/腫瘤分析市場受到基因組學和蛋白​​質組學技術的進步的推動，從而實現了精確的分子診斷。全球癌症發生率的不斷上升，加上個人化醫療需求的不斷成長，加速了癌症/腫瘤分析市場的成長。例如，2024 年 12 月，Aster DM Healthcare 宣佈在 Aster 癌症會議期間啟動三項計畫：精準腫瘤診所、Aster 癌症網格和 Onco Collect。這些計畫旨在透過基因組方法增強個人化數據驅動的癌症治療，促進合作研究並改善患者治療效果，使印度成為創新癌症治療的領導者。政府資助和私人投資對腫瘤學研究也扮演關鍵角色。下一代定序 (NGS) 和生物標記發現擴大用於早期檢測和標靶治療，而液體活體組織切片的技術創新提高了分析準確性並增強了市場擴張。

美國癌症/腫瘤分析市場受到癌症高發病率和個人化醫療需求不斷成長的推動。根據美國國家醫學圖書館發布的資料，預計到 2024 年，美國將新增 2,001,140 例癌症病例，並有 611,720 人死亡。下一代定序 (NGS) 等基因組和蛋白質組學技術的進步提高了腫瘤分析的準確性。政府對腫瘤學研究的大量資金和投資進一步支持了市場的成長。

癌症/腫瘤分析市場趨勢：

癌症發生率上升

全球癌症發生率的不斷上升為這一成長提供了相當大的推動力。癌症發生率正處於高峰期，隨著人們越來越關注準確和具體的診斷解決方案以改善患者的治療效果，對腫瘤分析的先進方法的需求每年都在增加。美國癌症協會報告稱，2022年全球診斷出近2,000萬例癌症，導致970萬人死於癌症。這一令人擔憂的趨勢凸顯了對更好的診斷和治療方案的迫切需求。此外，預計到 2050 年，受人口老化、生活方式改變和環境影響等因素的影響，癌症病例數可能會上升到 3,500 萬人。這些統計數據表明，腫瘤分析在滿足客製化治療需求和提高癌症治療存活率方面發揮著越來越重要的作用。

基因組學和精準醫學的進展

包括NGS和蛋白質組學在內的基因組技術的進步徹底改變了癌症和治療過程的研究。正因如此，腫瘤分析市場才得以快速成長。利用這些先進的技術，可以實現全面的腫瘤分析，從而根據每個患者的基因組成製定個人化治療方案。治療效果不斷提高，更加重視為癌症患者提供精準的照護。報告顯示，2022年全球癌症藥物投資總額約1,960億美元，過去五年平均成長率約12%。對創新診斷和治療應用的需求不斷成長，導致人們擴大使用先進的基因組技術來分析腫瘤。這些發展改變了腫瘤學格局，為更有效、更有針對性的癌症治療開闢了道路，為癌症/腫瘤分析市場創造了積極的前景。

政府和研究經費

癌症和精準醫療的投資和資金正在大幅成長，從而促進了腫瘤分析。政府、製藥公司和其他研究機構合作開發更先進的分析解決方案，加速癌症早期診斷和治療方法的進步。根據英國癌症研究中心報道，英國政府承諾2027年將研發總投資增加到GDP的2.4%。這些項目強調了人們對癌症診斷和治療創新的日益關注，這推動了癌症/腫瘤分析市場的需求。這些投資不僅使精準醫療更容易獲得，而且推動了癌症個人化治療的突破性創新，從而推動了市場成長。

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

  • 概述
  • 主要行業趨勢

第5章：全球癌症/腫瘤分析市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依癌症類型

  • 乳癌
  • 肺癌
  • 大腸直腸癌
  • 攝護腺癌
  • 黑色素瘤癌症
  • 其他

第7章：市場區隔：依技術

  • 下一代定序（NGS）
  • 聚合酶鍊式反應（PCR）
  • 免疫組織化學（IHC）
  • 原位雜合技術（ISH）
  • 微陣列
  • 其他

第8章：市場區隔：依技術

  • 基因組學
  • 蛋白質體學
  • 表觀遺傳學
  • 代謝組學

第9章：市場區隔：依應用

  • 個人化醫療
  • 診斷
  • 生物標記發現
  • 預測
  • 其他

第10章：市場細分：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔：依國家

第 11 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章：價值鏈分析

第 13 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章：價格分析

第 15 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • Becton Dickinson and Company
    • Caris Life Sciences
    • Exact Sciences Corporation
    • F. Hoffmann-La Roche Ltd
    • Hologic Inc.
    • HTG Molecular Diagnostics Inc.
    • Illumina Inc.
    • Laboratory Corporation of America Holdings
    • NeoGenomics Laboratories
    • Qiagen NV
    • Siemens AG
    • Sysmex Corporation
Product Code: SR112025A5231

The global cancer/tumor profiling market size was valued at USD 12.47 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 26.29 Billion by 2033, exhibiting a CAGR of 8.21% during 2025-2033. North America currently dominates the market, holding a significant market share of over 42.8% in 2024. The market is experiencing significant growth driven by advancements in precision medicine, rising cancer prevalence and increasing adoption of personalized treatment approaches. Growing demand for biomarker-based diagnostics coupled with technological innovations in genomic and proteomic profiling, further fuels market expansion.

The cancer/tumor profiling market is driven by advancements in genomic and proteomic technologies enabling precise molecular diagnostics. Increasing prevalence of cancer globally coupled with the rising demand for personalized medicine accelerates cancer/tumor profiling market growth. For instance, in December 2024, Aster DM Healthcare announced the launch three initiatives Precision Oncology Clinics, the Aster Cancer Grid and Onco Collect during the Aster Cancer Conclave. These programs aim to enhance personalized data-driven cancer care through genomic approaches promote collaborative research and improve patient outcomes positioning India as a leader in innovative cancer treatment. Government funding and private investments in oncology research also play a pivotal role. Next-generation sequencing (NGS) and biomarker discovery are becoming increasingly adopted for early detection and targeted therapies while technological innovations in liquid biopsy improve profiling accuracy and enhance market expansion.

The United States cancer/tumor profiling market is driven by the high prevalence of cancer and the increasing demand for personalized medicine. According to the data published by the National Library of Medicine, in 2024 an estimated 2,001,140 new cancer cases and 611,720 deaths are projected in the U.S. Advancements in genomic and proteomic technologies such as next-generation sequencing (NGS) enhance the accuracy of tumor profiling. Substantial government funding and investments in oncology research further support market growth.

Cancer/Tumor Profiling Market Trends:

Rising Prevalence of Cancer

The increasing prevalence of cancer in the world has provided a considerable thrust to this growth. Cancer incidence is at its peak, as with an ever-growing focus on exact and specific diagnosis solutions towards the betterment of patient results, the necessity of advanced methods for tumor profiling keeps increasing every year. The American Cancer Society reported that nearly 20 million cases of cancer were diagnosed worldwide in 2022, resulting in 9.7 million deaths due to the disease. This concerning trend highlights the urgent need for better diagnostic and treatment options. Additionally, it is projected that the number of cancer cases could rise to 35 million by 2050, driven by factors such as an aging population, lifestyle changes, and environmental impacts. These statistics point out how tumor profiling plays an increasingly pivotal role in serving the needs for tailored therapies and improved survival in cancer care.

Advancements in Genomics and Precision Medicine

Advances in genomic technologies, including NGS and proteomics, have revolutionized the study of cancer and treatment processes. It is because of this that growth in the tumor profiling market has taken a massive pace. With such advanced technologies, comprehensive tumor profiling is achieved that leads to developing personalized therapies on the basis of the genetic make-up of each individual patient. The results of treatment are improving, and there is a greater emphasis on providing precise care for cancer patients. Reports indicate that global investments in cancer medicine totaled around USD 196 billion in 2022, with an average growth rate of approximately 12% over the last five years. The growing requirement for innovative diagnostics and therapeutic applications has led to an increased utilization of advanced genomic technologies for profiling tumors. These developments are creating positive cancer/tumor profiling market outlook by changing the oncology landscape, opening the way for more effective and targeted cancer treatments.

Government and Research Funding

Investment and funding for cancer and precision medicine are growing largely and thus boosting tumor profiling. The governments, pharmaceutical companies, and other research organizations collaborate on the development of more advanced profiling solutions, which speed up the advancement in early diagnosis and treatment methods for cancer. The UK Government has committed to increasing its total investment in research and development (R&D) to 2.4% of GDP by the year 2027, as reported by Cancer Research UK. Such programs underscore the growing focus on innovation in cancer diagnostics and treatments, which drives cancer/tumor profiling market demand. These investments do not only make precision medicine more accessible but also fuel breakthrough innovations in the personalized treatment of cancer, thereby fueling the market growth.

Cancer/Tumor Profiling Industry Segmentation:

Analysis by Cancer Type:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma Cancer
  • Others

Breast cancer leads the cancer/tumor profiling market due to its high global prevalence and the increasing adoption of personalized medicine in oncology. Advanced profiling techniques such as next-generation sequencing (NGS) and immunohistochemistry (IHC) play a crucial role in identifying biomarkers for targeted therapies improving patient outcomes. The growing focus on early detection coupled with the rising availability of breast cancer-specific diagnostic tests and therapies drives market growth. Continuous research efforts and clinical trials further strengthen breast cancer's leadership in this sector.

Analysis by Technology:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • In-Situ Hybridization (ISH)
  • Microarray
  • Others

NGS is one of the most prominent technologies in the cancer/tumor profiling market which enables the comprehensive genomic analysis for identifying cancer mutations and biomarkers. Its high-throughput capability and precision facilitate personalized treatments and diagnostics. Increasing adoption of NGS in clinical oncology and its application in targeted therapies and companion diagnostics significantly drive its demand in cancer profiling research.

PCR is highly used in cancer/tumor profiling because of its high sensitivity and specificity in detecting genetic mutations and alterations. It is also very important in the analysis of minimal DNA samples which makes it ideal for early cancer detection. The advancements in real-time and digital PCR further enhance its utility which has fostered its growth as a critical technology in oncology diagnostics.

IHC is one of the core technologies used to identify the tumor's specific protein and biomarkers profiles. This method's usefulness in finding hormone receptors status for example in breast cancer is confirmed by determining the expression of HER2 in cancer. IHC supports personalized treatment approaches through the selection of targeted therapies by a clinician based on biomarker expression patterns.

ISH technology is also used for cancer profiling. This technology can accurately visualize genetic abnormalities directly in tissue samples. It is highly efficient in detecting gene amplifications, translocations and deletions. Applications include the identification of HER2/neu in breast cancer and other chromosomal aberrations. Its use is continuously propelled by the rising demand for accurate molecular diagnostics.

Microarray technology supports cancer profiling by analyzing gene expression patterns and identifying biomarkers associated with tumor development. It enables large-scale screening of genetic data providing insights into cancer classification and progression. The utility of the technology in discovering therapeutic targets and stratifying patients for clinical trials makes it a valuable tool in oncology research and diagnostics.

Analysis by Technique:

  • Genomics
  • Proteomics
  • Epigenetics
  • Metabolomics

Genomics leads the market with around 39.8% of cancer/tumor profiling market share in 2024. Genomics is the largest technique in the cancer/tumor profiling market because it plays a central role in understanding the genetic basis of cancer. Genomic profiling allows for the identification of mutations, gene expression patterns and biomarkers critical for personalized oncology. Technologies such as next-generation sequencing (NGS) and microarrays drive this segment by offering high-throughput and precise analyses. The rise in targeted therapies advancements in companion diagnostics and the increasing adoption of genomics within clinical oncology heighten its presence further while promoting successful treatment outcomes and new areas for research.

Analysis by Application:

  • Personalized Medicine
  • Diagnostics
  • Biomarker Discovery
  • Prognostics
  • Others

The personalized medicine segment is highly important in the cancer/tumor profiling market as it provides for treatment based on an individual's genetic and molecular profile. This improves the effectiveness of therapy while minimizing side effects targeting the specific biomarkers. Increasing precision oncology adoption and advancement in tumor profiling techniques propel this segment's growth significantly which also enhances patient outcomes.

The market is dominated by the diagnostics segment mainly because of the accurate type and stage of cancer identification via advanced tumour profiling techniques. Technologies such as PCR, NGS and IHC enable early diagnosis and improved decision-making in treatment plans. The demand for early screening of cancer and non-invasive diagnostic solutions is therefore driving further expansion in this critical application area.

Biomarker discovery is one of the key applications of cancer profiling focused on identifying molecular markers associated with cancer development and progression. This helps in targeted drug development and companion diagnostics that drive the evolution of precision medicine. Continuous genomics and proteomics research coupled with increased investments in oncology studies propel this segment in the market.

The prognostics segment is used to predict the progression of cancer, survival rate of patients and possible treatment response through tumor profiling. It supports the planning of treatment on an individual basis by analyzing genetic mutations and biomarkers. Rising awareness of the benefits of prognostic tools and advancements in molecular diagnostics contribute to the growing adoption of prognostic applications in the cancer/tumor profiling market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America accounted for the largest market share of over 42.8%. North America dominates the cancer/tumor profiling market with the region witnessing an advanced healthcare infrastructure, high adoption of precision medicine and substantial investments in oncology research. The region benefits from the widespread availability of advanced diagnostic technologies such as NGS and PCR along with a strong presence of key market players. Rising cancer prevalence and government initiatives to support cancer screening and biomarker research further propel market growth. With higher clinical trials and research collaborations among research institutes North America leads this market.

Key Regional Takeaways:

United States Cancer/Tumor Profiling Market Analysis

In 2024, the United States captured 88.9% of revenue in the North American market. The American Cancer Society anticipates more than 1.9 million new cancer cases in the U.S. for 2024. It's estimated that 1 in 23 men and 1 in 24 women will be diagnosed with colorectal cancer at some point in their lives. Current projections for 2023 suggest that there will be 106,970 new cases of colon cancer and 46,050 new cases of rectal cancer in the U.S. With this trend in cancer, growing need is being seen to develop diagnostic and prognostic tools at more advanced levels such as tumor profiling. Tumor profiling provides more informative molecular data which helps identify mutations, biomarkers, and targets of therapy. As healthcare systems look to the earlier diagnosis and tailoring of therapy to improve outcomes in patients there will be immense opportunities for the growth of the cancer/tumor profiling market.

Europe Cancer/Tumor Profiling Market Analysis

The Europe cancer/tumor profiling market is experiencing significant growth driven by the rising burden of cancer particularly due to an ageing population. From 2010 to 2020, the European population living with cancer saw an annual increase of 3.5% leading to an overall rise of 41% according to the EU Science Hub. With the aging population the prevalence of cancer is anticipated to grow which will increase the need for advanced diagnostic technologies such as tumor profiling. These technologies such as next-generation sequencing (NGS) and liquid biopsy enable early cancer detection and personalized treatment strategies improving patient outcomes. With an increased focus on precision medicine and the growing recognition of the benefits of early and accurate cancer detection Europe is seeing an uptick in the adoption of tumor profiling solutions. Additionally, the region's strong healthcare infrastructure and government support for cancer research are expected to continue driving market expansion in the coming years.

Asia Pacific Cancer/Tumor Profiling Market Analysis

The Asia Pacific region experiences a considerable burden from cancer with the five most prevalent types being lung cancer (1,315,136 new cases), breast cancer (1,026,171 cases), colorectal cancer (1,009,400 cases), stomach cancer (819,944 cases) and liver cancer (656,992 cases) as reported by NIH data. This rising incidence is fueling the demand for advanced cancer diagnostics including tumor profiling technologies like next-generation sequencing (NGS) and liquid biopsy. As healthcare infrastructure improves across countries like China, India and Japan there is a strong push for precision medicine and personalized therapies. These innovations are driving the adoption of tumor profiling tools to enhance early detection, guide treatment decisions and improve patient outcomes. Government initiatives, increased healthcare spending and strategic partnerships with global biotech and pharmaceutical firms are accelerating the adoption of these technologies in the region. The Asia Pacific cancer/tumor profiling market is poised for significant growth driven by the need for more effective tailored cancer care solutions.

Latin America Cancer/Tumor Profiling Market Analysis

As cited by the ESMO 2022 report Latin America presents a significant burden of cancer. An estimated 1.5 million new cases and 700,000 deaths are reported yearly. The cancer incidence and mortality rates in this region stand at 186.5 and 86.6 per 100,000, indicating a pressing requirement for advanced diagnostic solutions. Cancer has recently been a new tool for tackling cancer by way of personalising the treatment processes to suit every patient's specific genetic makeup. This, besides enhancing patient results, has managed to tackle cancer mortality rates across the region. Governments in Latin America are pouring more investments in healthcare infrastructure; the emphasis lies on early detection and precision medicine to curb rising cancer burdens. The innovation in diagnostic techniques is driven by collaborations between regional healthcare providers and global biotechnology firms, increasing access to next-generation sequencing and other tumor profiling technologies. Such efforts are expected to fuel the growth of the tumor profiling market, bringing hope for better cancer management across the region.

Middle East and Africa Cancer/Tumor Profiling Market Analysis

The Middle East and Africa (MEA) region is undergoing a significant change in the increasing number of cancer cases. Ingestion of lifestyle changes, aging populations, and a burgeoning environmental risk factor are widespread. Cancer incidence is projected to increase 1.8-fold by 2030 in Arab countries, according to the NIH, further necessitating advanced diagnostic and treatment solutions. The demand for cancer/tumor profiling is accelerating as healthcare systems in the region focus on early detection and personalized treatment approaches to improve patient outcomes. Governments and private organizations are increasingly investing in healthcare infrastructure, research initiatives, and collaborations with global biotechnology companies to bring state-of-the-art technologies, such as next-generation sequencing (NGS) and liquid biopsy solutions, to the region. It can be attributed to the presence of initiatives like UAE National Cancer Registry and healthcare targets set in Saudi Arabia through its Vision 2030, leading to an advance in cancer profiling. This, too, will foster growth for the MEA market on cancer/tumor profiling.

Competitive Landscape:

The cancer/tumor profiling market is highly competitive with key players focusing on innovation, strategic partnerships and product development to strengthen their market presence. Leading companies are driving advancements in genomic and molecular diagnostics. These firms invest heavily in research and development to introduce advanced profiling technologies such as NGS and biomarker-based diagnostics. Additionally, collaborations between biotechnology companies, research institutions and healthcare providers are fueling market expansion. Emerging players are also leveraging technological advancements and targeting niche segments to gain a competitive edge further intensifying the market's dynamic landscape.

The report provides a comprehensive analysis of the competitive landscape in the cancer tumor profiling market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • Becton Dickinson and Company
  • Caris Life Sciences
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Hologic Inc.
  • HTG Molecular Diagnostics Inc.
  • Illumina Inc.
  • Laboratory Corporation of America Holdings
  • NeoGenomics Laboratories
  • Qiagen N.V.
  • Siemens AG
  • Sysmex Corporation

Latest News and Developments:

  • October 2024: Illumina announced its partnership with AstraZeneca to develop innovative next-generation sequencing (NGS)-based companion diagnostics, strengthening its capabilities in oncology-related solutions.
  • September 2024: Thermo Fisher launched the Oncomine Comprehensive Assay Plus, a targeted NGS tool designed to detect essential mutations in solid tumors, demonstrating its dedication to improving diagnostic options in cancer genomics.
  • November 2023: Illumina unveiled the latest version of its liquid biopsy assay for genomic profiling, the TruSight Oncology 500 ctDNA v2. This assay is intended to deliver thorough genomic insights from blood samples, especially useful for patients when tissue testing is not feasible.
  • May 2023: Pfizer announced its partnership with Thermo Fisher Scientific in a strategic collaboration aimed at increasing the availability of NGS-based testing for lung and breast cancer patients across more than 30 countries.

Key Questions Answered in This Report

  • 1.How big is the cancer/tumor profiling market?
  • 2.What is the future outlook of cancer/tumor profiling market?
  • 3.What are the key factors driving the cancer/tumor profiling market?
  • 4.Which region accounts for the largest cancer/tumor profiling market share?
  • 5.Which are the leading companies in the global cancer/tumor profiling market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer/Tumor Profiling Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Cancer Type

  • 6.1 Breast Cancer
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Lung Cancer
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Colorectal Cancer
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Prostate Cancer
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Melanoma Cancer
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Next-Generation Sequencing (NGS)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Polymerase Chain Reaction (PCR)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Immunohistochemistry (IHC)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 In-Situ Hybridization (ISH)
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Microarray
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Technique

  • 8.1 Genomics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Proteomics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Epigenetics
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Metabolomics
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Personalized Medicine
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Diagnostics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Biomarker Discovery
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Prognostics
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Becton Dickinson and Company
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Caris Life Sciences
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Exact Sciences Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche Ltd
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Hologic Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 HTG Molecular Diagnostics Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 Illumina Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Laboratory Corporation of America Holdings
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 NeoGenomics Laboratories
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
    • 15.3.11 Qiagen N.V.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Siemens AG
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Sysmex Corporation
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cancer/Tumor Profiling Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer/Tumor Profiling Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Cancer/Tumor Profiling Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Cancer/Tumor Profiling Market: Breakup by Cancer Type (in %), 2024
  • Figure 5: Global: Cancer/Tumor Profiling Market: Breakup by Technology (in %), 2024
  • Figure 6: Global: Cancer/Tumor Profiling Market: Breakup by Technique (in %), 2024
  • Figure 7: Global: Cancer/Tumor Profiling Market: Breakup by Application (in %), 2024
  • Figure 8: Global: Cancer/Tumor Profiling Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Cancer/Tumor Profiling (Breast Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Cancer/Tumor Profiling (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Cancer/Tumor Profiling (Lung Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Cancer/Tumor Profiling (Lung Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Cancer/Tumor Profiling (Colorectal Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Cancer/Tumor Profiling (Colorectal Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Cancer/Tumor Profiling (Prostate Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Cancer/Tumor Profiling (Prostate Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Cancer/Tumor Profiling (Melanoma Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Cancer/Tumor Profiling (Melanoma Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Cancer/Tumor Profiling (Other Cancer Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Cancer/Tumor Profiling (Other Cancer Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Cancer/Tumor Profiling (Next-Generation Sequencing-NGS) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Cancer/Tumor Profiling (Next-Generation Sequencing-NGS) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Cancer/Tumor Profiling (Polymerase Chain Reaction-PCR) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Cancer/Tumor Profiling (Polymerase Chain Reaction-PCR) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Cancer/Tumor Profiling (Immunohistochemistry-IHC) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Cancer/Tumor Profiling (Immunohistochemistry-IHC) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Cancer/Tumor Profiling (In-Situ Hybridization-ISH) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Cancer/Tumor Profiling (In-Situ Hybridization-ISH) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Cancer/Tumor Profiling (Microarray) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Cancer/Tumor Profiling (Microarray) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Cancer/Tumor Profiling (Other Technologies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Cancer/Tumor Profiling (Other Technologies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Cancer/Tumor Profiling (Genomics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Cancer/Tumor Profiling (Genomics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Cancer/Tumor Profiling (Proteomics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Cancer/Tumor Profiling (Proteomics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Cancer/Tumor Profiling (Epigenetics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Cancer/Tumor Profiling (Epigenetics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Cancer/Tumor Profiling (Metabolomics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Cancer/Tumor Profiling (Metabolomics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Global: Cancer/Tumor Profiling (Personalized Medicine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Global: Cancer/Tumor Profiling (Personalized Medicine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Global: Cancer/Tumor Profiling (Diagnostics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Global: Cancer/Tumor Profiling (Diagnostics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Global: Cancer/Tumor Profiling (Biomarker Discovery) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Global: Cancer/Tumor Profiling (Biomarker Discovery) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Global: Cancer/Tumor Profiling (Prognostics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Global: Cancer/Tumor Profiling (Prognostics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Global: Cancer/Tumor Profiling (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Global: Cancer/Tumor Profiling (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: North America: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: North America: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: United States: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: United States: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Canada: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Canada: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Asia-Pacific: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Asia-Pacific: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: China: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: China: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Japan: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Japan: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: India: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: India: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: South Korea: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: South Korea: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Australia: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Australia: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Indonesia: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Indonesia: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Others: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Others: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Europe: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Europe: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Germany: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Germany: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: France: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: France: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: United Kingdom: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: United Kingdom: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Italy: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Italy: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Spain: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Spain: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Russia: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Russia: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Others: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Others: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Latin America: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 90: Latin America: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 91: Brazil: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 92: Brazil: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 93: Mexico: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 94: Mexico: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 95: Others: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 96: Others: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 97: Middle East and Africa: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 98: Middle East and Africa: Cancer/Tumor Profiling Market: Breakup by Country (in %), 2024
  • Figure 99: Middle East and Africa: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 100: Global: Cancer/Tumor Profiling Industry: SWOT Analysis
  • Figure 101: Global: Cancer/Tumor Profiling Industry: Value Chain Analysis
  • Figure 102: Global: Cancer/Tumor Profiling Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer/Tumor Profiling Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Cancer/Tumor Profiling Market Forecast: Breakup by Cancer Type (in Million USD), 2025-2033
  • Table 3: Global: Cancer/Tumor Profiling Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 4: Global: Cancer/Tumor Profiling Market Forecast: Breakup by Technique (in Million USD), 2025-2033
  • Table 5: Global: Cancer/Tumor Profiling Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 6: Global: Cancer/Tumor Profiling Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Cancer/Tumor Profiling Market: Competitive Structure
  • Table 8: Global: Cancer/Tumor Profiling Market: Key Players